Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD107m

    Last close

    AUD0.02

    ▲ 0.01 (100.00%)

    Silver Spruce Resources

    MCap

    CAD5m

    Last close

    CAD0.03

    ▲ 0.01 (50.00%)

    Context Therapeutics

    MCap

    USD16m

    Last close

    USD1.00

    ▲ 0.32 (47.06%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Actinogen Medical (ASX: ACW)

Currency in AUD

Last close As at 03/02/2023

AUD0.09

— 0.00 (0.00%)

Market capitalisation

AUD172m

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat CI that occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date. The XanaCIDD study may also validate the drug’s potential for treating CI related to MDD.

Latest Insights

View More

Healthcare

Actinogen Medical — XanaMIA clears hurdle to start US recruitment

Healthcare

Actinogen Medical — XanaCIDD study in MDD now underway

Healthcare

Actinogen Medical – executive interview

Actinogen Medical — Cognitive enhancer targeting key diseases
Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Pooya Hemami

Analyst

Key Management

  • Dr Steven Gourlay

    CEO and MD

Balance Sheet

Forecast net cash (A$m)

7

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (7.1) (24.2) (20.9)
Relative (12.0) (31.0) (25.4)
52 week high/low A$0.1/A$0.0

Financials

Actinogen has announced that the US FDA has provided the required approvals for it to proceed with US recruitment for its planned six-month, placebo-controlled Phase IIb portion of the XanaMIA study. This study is designed to demonstrate the safety and efficacy of Xanamem in a population of patients with mild cognitive impairment and mild Alzheimer’s disease (AD), who at baseline will have been confirmed as biomarker-positive for AD (as determined through elevated blood phosphorylated Tau, or pTau). The study will start enrolment in H1 CY23 and results are expected in late CY24.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.0 (3.5) (3.3) (0.236) N/A N/A
2022A 3.6 (9.1) (7.9) (0.460) N/A N/A
2023E 3.6 (8.2) (8.7) (0.482) N/A N/A
2024E 3.3 (37.4) (38.7) (2.153) N/A N/A

Research

View All

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free